VERAXA Biotech AG (VRXA), a cancer therapeutics company, announced on Friday the appointment of Raju Willener as its new Chief Financial Officer (CFO).
Willener succeeds Carl von Halem, who stepped in as interim CFO after Torsten Burgermeister departed the role in July 2026. Burgermeister had led the company through its transition to a publicly traded entity in June 2026.
The company noted that Willener brings three decades of financial leadership experience, having previously held roles such as CFO, Chief Investment Officer, Country Head, and Head of Corporate Finance. Most recently, he served as Director of Corporate Development and subsequently as CFO at Exentis AG. He has also held senior executive and investment leadership positions at various investment firms and global financial institutions.
VERAXA is currently advancing a diversified pipeline of active T-cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats toward clinical development.
Shares of VRXA closed Thursday at $1.53, reflecting a gain of 10.87%.
Also Read
- UN General Assembly Set to Consider African-Led Initiative for a More Accurate World Map
- US Envoys to Engage in Critical Talks with Putin and Zelensky This Weekend
- Viral Little League Coach’s Dugout Speech Offers Timeless Leadership Wisdom for Business
- Wall Street Roundup: Key Analyst Upgrades, Price Target Revisions, and New Initiations